Ticagrelor Plus Aspirin Versus Aspirin Alone After Heart Bypass Surgery
Compares ticagrelor with aspirin against aspirin alone in adults with heart disease having bypass surgery.
Plain-language title generated from the registry record
Registry title: One-Month DAPT in CABG Patients
Key facts
- Where
- Goteborg and Lund, SwedenSee the 2 sites
- Phase
- Phase 3
Where in Sweden
- Sahlgrenska University Hospital-Vastra GotalandsregionenGoteborg, SwedenTaking people
- Region Skane Skanes UniversitetssjukhusLund, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Weill Medical College of Cornell University
- Trial code
- NCT05997693EU 2023-506613-22-00
- Record updated
- 22 December 2025
- Original description
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.Read full original descriptionShow less
One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Inclusion: Age ≥18 years; Elective first-time CABG with use of ≥1 saphenous vein graft; Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years.
Exclusion: Any indication for dual antiplatelet therapy, including; Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI); Recent PCI requiring continuation of dual antiplatelet therapy after CABG; Any concomitant cardiac or non-cardiac procedure; Contraindications to the use of ticagrelor, including; Known hypersensitivity to ticagrelor; Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding); History of intracranial hemorrhage; Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir); Participating in another investigational device or drug study; Planned cardiac or non-cardiac surgery within one year; Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis; Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy <5 years; Current or anticipated use of oral anticoagulation; Paroxysmal, persistent or permanent atrial fibrillation; Inability to use the saphenous vein; Contraindications to the use of aspirin; Inability to undergo coronary computed tomographic angiography (CCTA); Women of childbearing potential.